Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's all about the paragraphs. ;)
A bit more readable.
TEDT9 from Yahoo board:
FACT:
Cel-Sci's Multikine therapy was granted Orphan Drug status by the FDA.
FACT:
In the most recent Phase 2 clinical trial, CEL-SCI reported a 10.5% complete response rate (no clinical or pathology evidence of any remaining cancer) and a 33% improvement in overall survival after just three weeks of treatment. NO serious adverse events were reported associated with Multikine.
Rest assured Multikine will exceed the 10% over SOC required.
FACT:
Phase 3 trial lasted over 2 years longer than it was expected to last. This suggests Multikine is working exceptionally well.
FACT:
Normal time from last event to data lock: approximately 21 days. Approximate time from lock to data read [analysis?], 4 to 6 weeks. According to the statisticians I have heard from, there have been cases where data input was loaded in the computer program in 40 to 60 hours.
FACT:
End of the Phase 3 trial (the last event) was confirmed May 4th 2020, which tells you how close we are to the positive top line data release we have been waiting for.
And don't forget that the reconstitution of the Russel 3000 portfolio announced on June 5 should put upward pressure on share price -- not to mention covering 6 MILLION shorted shares.
TGLO: whats the current zeitgeist on this?
Owned mostly by Delfin Midstream LLC some years now (71%+), still kept fully-reporting, presumably as a possible R/M option.
Frederick Jones, CEO/CFO/COO/etc of TGLO (and a founder of Glencore's predecessor), was this Jan. appointed to the bod of Bluewater Acquisition. Bluewater is a Canadian public shell looking for a private maritime to execute a R/M with. Don't know if that has, or will have, anything directly to do with TGLO, or even with Delfin.
I keep thinking wheels are turning with TGLO. But which way?
I suspect it's due to fear of lawyers.
[Note: the following is raw speculation and a lot of thinking-out-loud.]
Bluewater Acquisition is a "capital pool" company (a CPC) on the Toronto Exchange, about 7 million shares outstanding. In Canada, capital pool companies are public shell companies created solely to conduct reverse mergers, if they can find a target company. A CPC has two years after its IPO to complete a "qualifying tranasction."
I suppose if Bluewater reverse-merged with Delphin, Delphin would not need TGLO anymore and we'd be screwed. But might Delphin's TGLO shares instead provide an easy vehicle for Bluewater to, at the same time, get listed on a US exchange? (And, ipso facto, get Delphin trading on the TSX, fwiw?) Where does it say that a public shell can't merge with another public shell?
If Bluewater is even looking at Delphin. Can CPCs merge with foreign companies?
Bluewater Delphin... what a great name. Right out of suspense novel.
hmmmm...
www.investopedia.com/terms/q/qualifying-transaction.asp
Just ran across this from January.
Mentions an impending "qualifying transaction" that as of May 1 is/was still impending, and Bluewater cannot conduct any business until transaction is completed. Direct relevance to Delfin and TGLO unknown.
Bluewater Acquisition Corp. announces appointment of Frederick Jones as Special Advisor to Board of Directors
CALGARY, Alberta, Jan. 06, 2020
Bluewater Acquisition Corp. (TSXV: BAQ.P) ("Bluewater"), a capital pool company with the aim of identifying and investing in assets and businesses in the maritime/shipping sector, is pleased to announce the appointment of Frederick Jones as Special Advisor to the board of directors.
For several months, Mr. Jones has been working closely with the board and management of Bluewater to achieve their goal of consummating a Qualifying Transaction in the maritime shipping industry.
Peter Karos, President and Chief Executive Officer of Bluewater, stated: “We are very excited to have Fred join Bluewater as Special Advisor to the Board. Fred’s depth and breadth of experience in the global commodities and maritime shipping industry is unparalleled. His relationships within industry will give us a significant advantage as we look to complete our Qualifying Transaction this year.”
Mr. Jones has over 40 years of experience in the energy industry, commodities industry and maritime shipping industry. He was a founding shareholder and partner of Marc Rich + Co which was the precursor firm to what is now Glencore PLC. Mr. Jones also served as an advisor to the President of the Organization of the Petroleum Exporting Countries (“OPEC”).
Over his four decade career, Mr. Jones has developed projects and businesses in LPG marketing, coalbed methane extraction, hydroelectric power sector and natural gas sector . He has served as an officer in both publicly listed and privately-held companies.
Mr. Jones is the founder of Delfin LNG which is the first and only permitted floating LNG project in the US. Mr. Jones continues to serve on the board of directors of Delfin.
About Bluewater
Bluewater is a newly-formed capital pool company created to identify and evaluate potential acquisitions of commercially viable businesses and assets in the maritime/shipping sector that have the potential to generate profits and add shareholder value. Except as specifically contemplated in Policy 2.4 of the TSXV, until the completion of a qualifying transaction, Bluewater will not carry on business, other than the identification and evaluation of businesses or assets with a view to completing a qualifying transaction. For more information please see www.bluewateracquisition.com.
what's with all the ambulance-chasers?
Not to ring a cracked bell or anything, but does 298th happening now tell us anything new about possible dropout rate?
I was scanning finviz for interesting beaten-down low-priced stuff with good fundamentals that looked ready to head back up again. Got in at 8.90 -- just before the crash. :(
I was with a youth tennis group that met sometimes at the Little Silver Racquet Club... yearssssss ago...
Lived in Middletown. Knew the Van Zandts.
I grew up in NJ near Red Bank
whereabouts on the E coast?
dodging the tornadoes in Mississippi
That being said...
I knew the NYT had embarked on a steeper downslope when, on the first page of their Jan. 1st 2000 issue, they ran a sappy group-Kumbaya photo of a small crowd of people staring past the camera at seemingly nothing in particular. (Presumably they were watching the ball come down, or fireworks, but how did one really know for sure?)
It was like running a photo of a palm tree the day after Pearl Harbor.
and look at those insider buys, nice
I had the privilege of meeting Charlton Heston back in '77 at Upsala College in NJ. I was a ballboy at a celebrity tennis match on the "King of the Hill" circuit. Super-nice guy.
Looks like an easy double from here and with a great divy.
hydrochloroquine is stealing a lot of thunder out there
pretty quiet here for such a promising product
Back in at 13 even. Will watch for chance to fully re-occupy my forward foxhole.
Somewhat OT, and a heads-up:
It has been verified that 80mg to 92mg daily of elementary zinc will shorten the duration of a cold and diminish its severity. (An overabundance of zinc interferes with viral replication in many virus families, including coronaviruses.) Most colds are caused by the rhinovirus family of viruses, but coronaviruses are also commonly implicated.
I'm stocking up on zinc-acetate lozenges. Zinc acetate reportedly is more effective than the more commonly-available zinc gluconate.
Not to sound cynical, but when has an SEC investigation ever nabbed anyone responsible for similar shenanigans?
I got spooked out at 8.62 with over 4000sh. Still made a double-bagger and plus, though.
But for what? Now I'm looking at the AH in the $11 range. God knows what it will open at tomorrow.
I had to bail. I didn't know what was going on. No one did. How much lower was it going to go? Again, no one knew.
Now it seems to have been nothing more than a "short attack"?
For fuck's sake, why is "shorting" even allowed in the first place? You can borrow shares to sell at price X, with the expectation the price will drop, so you can buy them back and keep the difference? How is that even moral? Why is that even legal?
Maybe I'm just ignorant, or just naturally impatient. But there are no curses available to describe how enraged I am.
I'm no Democrat, but that almost sounds like 'fake news'. How can Sanders, who has spent so much of his life in Vermont, have no knowledge at all of that motto on car tags from neighboring New Hampshire?
Did Bernie have a "Biden moment"? Has he never seen that final-season episode from Breaking Bad?
I worry that Cel-Sci might become a victim of its own success. What if #298 ends up being so far off that in the meantime Multikine gets leapfrogged--or even just equaled--by some other company's tech?
And what if we get to December and they say, Extend the trial to March 2020?
interesting, at the very least. their US office is in Washington DC.
"API [Ample Power Investments] integrates the Natural Gas sector – from extraction to pipeline, processing to liquefaction, logistics to re-gasification, then delivery.
"By working with best-in-class partners, our seamless process delivers liquefied natural gas (LNG) to clients around the world. API also delivers crude and refined petroleum products, coal, power generation and renewable energy.
"Our global network, sector knowledge experienced team, and innovative practices make API a growing major player in the energy industry.
"API is now expanding its offering to physical elements of its business and is developing a significant portfolio of assets, including production, logistics and storage solutions.
"We are dedicated to environmentally responsible practices across our business chain."
in med school we had these nifty t-shirts: "I'LL SLEEP WHEN I'M DEAD."
I think I read here (or on Stocktwits) that Cel-Sci recently hired some professional statistical analysts.
Now, the IDMC can recommend terminating a study "for efficacy or futility."
Might Cel-Sci be prepping a case to transmit to the IDMC that strongly supports a "now-obvious efficacy"? (If such a thing is doable?)
Or maybe something to encourage the potential suitors out there.
Just thinking out loud.
Can the IDMC declare a drug or treatment efficacious (due to obvious benefit) but at the same time recommend that trial data collection continue?
This seems to imply that they're encountering a statistically-significant lower incidence of those conditions in the MK arm, and maybe even among the Phase 2 subjects. Very exciting.
good article, but why didnt he inquire about this pesky little penny shell called theglobe?
that's logical
What exactly does "follow" entail with the Mulitkine trial? I suppose it would be simple enough if all you need do was not lose track of patients' whereabouts, and whether or not they were still alive.
again, fwiw, the acc/distrib line still climbing. really jumped over the past 7 days
Accum/Dist still climbing, fwiw...
I concur, re Geert's citing of buyouts in the range of $5-$12 billion for small biotechs by big concerns. Why would he even mention those ?
now what's all that business about Talisman and "filer status"?